Clinical Trial Update: Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of romidepsin plus Abraxane in HER2-negative inflammatory and metastatic breast cancer was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Inflammatory Breast Cancer
• Male Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Romidepsin (romidepsin)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: HER2-negative Breast Cancer, Inflammatory Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-09-29